Ionotropic glutamate receptors: Still a target for neuroprotection in brain ischemia? Insights from in vitro studies

Neurobiology of Disease

Volumn 12, Issue 1, 2003, Pages 82-88

  Calabresi, Paolo ^a,b   Centonze, Diego ^a,b   Cupini, Letizia M ^a,b   Costa, Cinzia ^a,c   Pisani, Francesco ^c   Bernardi, Giorgio ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; IFENPRODIL; IONOTROPIC RECEPTOR; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; REMACEMIDE; SPIDER VENOM;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN ISCHEMIA; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG TARGETING; ELECTRIC POTENTIAL; GLUCOSE TRANSPORT; NEGATIVE FEEDBACK; NEUROPROTECTION; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT; SYNAPTIC TRANSMISSION;

EID: 0037327231     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-9961(02)00016-5     Document Type: Article

References (47)

1. Albers G.W., Atkinson R.P., Kelley R.E., Rosenbaum D.M. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke. 26:1995;254-258.
2. Alonso de Lecinana M., Diez-Tejedor E., Carceller F., Roda J.M. Cerebral ischemia from animal studies to clinical practice. Should the methods be reviewed? Cerebrovas. Dis. 11:(Suppl. 1):2001;20-30.
3. Arrowsmith J.E., Harrison M.J., Newman S.P., Stygall J., Timberlake N., Pugsley W.B. Neuroprotection of the brain during cardiopulmonary bypass a randomised trial of remacemide during coronary artery bypass in 171 patients . Stroke. 29:1998;2357-2362.
4. Bannan P.E., Graham D.I., Lees K.R., McCulloch J. Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the cat. Brain Res. 664:1994;271-275.
5. Bullock M.R., Merchant R.E., Carmack C.A., Doppenberg E., Shah A.K., Ko G., Williams S.A. An open-label study of CP-101,606 in subjects with severe traumatic head injury or spontaneous intracerebral hemorrage. Ann. N.Y. Acad. Sci. 890:1999;51-58.
6. Calabresi P., Pisani A., Mercuri N.B., Bernardi G. On the mechanisms underlying hypoxia-induced membrane depolarization in striatal neurons. Brain. 118:1995;1027-1038.
7. Calabresi P., Siniscalchi A., Pisani A., Stefani A., Mercuri N.B., Bernardi G. A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices. Neurology. 47:1996;557-562.
8. Calabresi P., Centonze D., Pisani A., Gubellini P., Marfia G.A., Bernardi G. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability implications for ischemia and Huntington's disease . Ann Neurol. 43:1998;586-597.
9. Calabresi M., Marfia G.A., Centonze D., Pisani A., Bernardi G. Sodium influx plays a major role in the membrane depolarization induced by oxygen and glucose deprivation in rat striatal neurons. Stroke. 30:1999;171-179.
10. Calabresi P., Centonze D., Bernardi G. Cellular factors controlling neuronal vulnerability in the brain. A lesson from the striatum. Neurology. 55:2000;1249-1255.
11. Calabresi P., Picconi B., Saulle E., Centonze D., Hainsworth A.H., Bernardi G. Is pharmacological neuroprotection dependent on reduced glutamate release? Stroke. 31:2000;766-773.
12. Caplan L.R. Stroke treatment promising but still struggling . J. Am. Med. Assoc. 279:1998;1304-1306.
13. Centonze D., Marfia G.A., Pisani A., Picconi B., Giacomini P., Bernardi G., Calabresi P. Ionic mechanisms underlying differential neuronal vulnerability in striatal neurons. Prog. Neurobiol. 63:2001;687-696.
14. Chiu D., Grotta J. Current status of cytoprotection. Welch K.M.A., Caplan L.R., Reis D.J., Siesjo B.O.K., Weir B. Primer on Cerebrovascular Diseases. 1997;731-737 Academic Press, San Diego.
15. Crumrine R.C., Bergstrand K., Cooper A.T., Faison W.L., Cooper B.R. Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest. Stroke. 11:1997;2230-2236.
16. Davies J.A. Remacemide hydrochloryde a novel antiepileptic agent . Gen. Pharmacol. 28:1997;499-502.
17. Davis S.M., Alberts G.W., Diener H.C., Lees K.R., Norris J. Termination of acute stroke studies involving selfotel treatment. Lancet. 349:1997;32.
18. De Keyser J., Sulter G., Luiten P.G. Clinical trials with neuroprotective drugs in acute ischemic stroke are we doing the right thing? Trends Neurosci. 22:1999;535-540.
19. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacol. Rev. 51:1999;7-61.
20. Dirnagl U., Iadecola C., Moskowitz M.A. Pathobiology of ischemic stroke. Trends Neurosci. 22:1999;391-397.
21. Dyker A.G., Lees K.R. Remacemide hydrochloride a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke . Stroke. 30:1999;1796-1801.
22. Hainsworth A.H., Stefani A., Calabresi P., Smith T.W., Leach M.J. Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor. C.N.S. Drug Rev. 6:2000;101-134.
23. Leach M.J., Marden C.M., Miller A.A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. II. Neurochemical studies on the mechanism of action. Epilepsia. 27:1986;490-497.
24. Lee J.-M., Zipfel G.J., Choi D.W. Changing landscape of ischaemic brain injury mechanisms. Nature. 399:(Suppl. 24):1999;A7-A14.
25. Lees K.R. Cerestat and other NMDA antagonists in ischemic stroke. Neurology. 49:(Suppl. 4):1997;66-69.
26. Lees K.R. Does neuroprotection improve stroke outcome? Lancet. 351:1998;1447-1448.
27. Lees K.R., Aspund K., Carolei A., et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke a randomised trial . Lancet 355. 2000;1949-1954.
28. Li S., Stys P.K. Mechanisms of ionotropic glutamate receptor-mediated excitoticity in isolated spinal cord white matter. J. Neurosci. 20:2000;1190-1198.
29. Martinez-Vila E., Sieira P.I. Current status and perspectives of neuroprotection in ischemic stroke treatment. Cerebrovasc. Dis. 11:(Suppl. 1):2001;60-70.
30. McNamara J.O. Drugs effective in the therapy of the epilepsies. Hardman J.G., Limbird L.E. Goodman & Gilman's The Pharmacological Bases of Therapeutics . 1996;461-486 McGraw-Hill, New York.
31. Meldrum B.S. Update on the mechanism of action of antiepileptic drugs. Epilepsia. 37:(Suppl. 6):1996;S4-S11.
32. Moshe S.L. Mechanisms of action of anticonvulsant agents. Neurology. 55:(Suppl. 1):2000;S32-S40.
33. Mott D.D., Doherty J.J., Zhang S., Washburn M.S., Fendley M.J., Lyuboslavsky P., Traynelis S.F., Dingledine R. Phenyletholamines inhibit NMDA receptors by enanching proton inhibition. Nature Neurosci. 1:1998;659-667.
34. Muir, K.W., Lees, K.R., & Hamilton, S.J.C. (1994) A randomised double blind, placebo controlled study of 619C89 in acute stroke (abstract). Proceedings of the 2nd International Conference on Neuroprotective Agents, Lake George.
35. Palmer G.C. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr. Drug Targets. 2:2001;241-271.
36. Palmer G.C., Cregan E.C., Borrelli A.R., Harris E.W., Stagnitto M.L., Colombo P., Kaiser F.C., Murray R.J., Griffith R.C., Strand J.C. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrocloride (FPL 13950) in animal models of hypoxia and global ischemia. J. Pharmacol. Exp. Ther. 274:1995;991-1000.
37. Pisani F., Pedale S., Macaione V., Torre V., Oteri G., Avanzini G., Ientile R. Neuroprotective effects of lamotrigine and remacemide on excitotoxicity induced by glutamate agonists in isolated chick retina. Exp. Neurol. 170:2001;162-170.
38. Plum F. Neuroprotection in acute ischemic stroke. J. Am. Med. Assoc. 13:2001;1760-1761.
39. Pulsinelli W.A., Mann M.E., Welch K.M.A., et al. Fosphophenytoin in acute ischemic stroke efficacy results . Neurology. 52:(Suppl. 2):1999;A384.
40. Rataud J., Debarnot F., Mary V., Pratt J., Stutzmann J.M. Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents. Neurosci. Lett. 172:1994;19-23.
41. Sacco R.L., DeRosa J.T., Haley E.C. Jr., Levin B., Ordronneau P., Phillips S.J., Rundek T., Snipes R.G., Thompson J.L. Glycine antagonist in neuroprotection for patients with acute stroke GAIN Americas a randomised controlled trial . J. Am. Med. Assoc. 285:2001;1719-1728.
42. +] in the hippocampus during recovery from short-term, transient ischemia . J. Cereb. Blood Flow Metab. 12:1992;759-772.
43. Small D.L., Buchan A.M. NMDA and AMPA receptor antagonists in global and focal ischemia. Welch K.M.A., Caplan L.R., Reis D.J., Siesjo B.O.K., Weir B. Primer on Cerebrovascular Diseases. 1997;244-250 Academic Press, San Diego.
44. Smith S.E., Meldrum B.S. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke. 26:1995;117-121.
45. Stefani A., Spadoni F., Bernardi G. Differential inhibition by riluzole, lamotrigine and phenitoin of sodium and calcium currents in cortical neurons implication for neuroprotective strategies . Exp. Neurol. 147:1997;115-122.
46. Wiard R.P., Dickerson M.C., Beek O., Norton R., Cooper B.R. Neuroprotective properties of the novel antiepileptic lamotrigine in a gerbil model of global cerebral ischemia. Stroke. 3:1995;466-472.
47. Ying H.S., Weishaupt J.H., Grabb M., Canzoniero L.M., Sensi S.L., Sheline C.T., Monyer H., Choi D.W. Sublethal oxygen-glucose deprivation alters hippocampal neuronal AMPA receptor expression and vulnerability to kainate-induced death. J. Neurosci. 17:1997;9536-9544.